Autonomix Medical Releases Clinical Data Showing Significant Pain Relief in Pancreatic Cancer

Autonomix Medical announced new subgroup clinical data from its PoC study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The analysis expands upon previously reported data from the Company's ongoing clinical evaluation and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related pain. The post hoc subgroup analysis expands upon previously reported findings from the Company's ongoing Proof-of-Concept 1 study, evaluating pancreatic cancer patients with severe baseline pain treated using a transvascular RF denervation platform. The analysis stratified outcomes by cancer stage, ranging from Stage 2 through Stage 4, and revealed consistent pain reduction regardless of disease severity. Key Findings: Pain Relief Observed Across All Stages of Pancreatic Cancer: Rapid onset effect: Responding patients demonstrated a marked reduction in average pain within 24 hours following the procedure. Early clinical impact: At 7-days post-procedure, 93.75% of responding patients improved from severe pain to mild or moderate pain, with several achieving near-elimination levels of pain with a score of 1 or 0 on the VAS scale. Sustained benefit: At 4-6-weeks post-procedure, approximately two-thirds of responding patients maintained pain at mild or elimination levels. Durability through 3 months: At 3-months post-procedure, no responding patients reported severe pain, and 50% maintained mild or eliminated pain levels. Late-stage disease: Even among late-stage cancer patients, meaningful improvement was observed. Several individuals with terminal disease reported a transition from severe to mild or moderate pain, at times even reporting near-elimination levels of pain relief. While disease progression limited longer-term follow-up in some cases, most reported substantial early improvement, underscoring the therapy's potential palliative impact in advanced pancreatic cancer.